A computational overview on phylogenetic characterization, pathogenic mutations, and drug targets for Ebola virus disease
| Autor: | Ramamoorthy Siva, Iftikhar Aslam Tayubi, N. Nagasundaram, Aisha Saleem, Karthick Vasudevan, D. Thirumal Kumar, S. Udhaya Kumar, Hatem Zayed, C. George Priya Doss |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
viruses
Biology medicine.disease_cause phylogeny Antibodies Monoclonal Humanized VP40 Phylogenetics Drug Discovery drug targets medicine Animals Humans Phylogeny Pharmacology chemistry.chemical_classification Viral matrix protein Ebola virus Phylogenetic tree Outbreak Hemorrhagic Fever Ebola Ebolavirus Virology Nucleoprotein Drug Combinations chemistry Ebola Mutation Glycoprotein |
| Zdroj: | Current opinion in pharmacology. 61 |
| ISSN: | 1471-4973 |
| Popis: | The World Health Organization declared Ebola virus disease (EVD) as the major outbreak in the 20th century. EVD was first identified in 1976 in South Sudan and the Democratic Republic of the Congo. EVD was transmitted from infected fruit bats to humans via contact with infected animal body fluids. The Ebola virus (EBOV) has a genome size of ∼18,959 bp. It encodes seven distinct proteins: nucleoprotein (NP), glycoprotein (GP), viral proteins VP24, VP30, VP35, matrix protein VP40, and polymerase L is considered a prime target for potential antiviral strategies. The current US FDA-approved anti-EVD vaccine, ERVERBO, and the other equally effective anti-EBOV combinations of three fully human monoclonal antibodies such as REGN-EB3, primarily target the envelope glycoprotein. This work elaborates on the EBOV's phylogenetic structure and the crucial mutations associated with viral pathogenicity. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect